Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
NCT02914665 is registered in ClinicalTrials.gov with Stealth BioTherapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 20, 2016
- Completion date
- November 27, 2017
- Enrollment
- 308 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.